Net Sales are expected to increase by 5.9 percent Q-o-Q (up 18.4 percent Y-o-Y) to Rs 3945.3 crore, according to Centrum.
Centrum's report on Aurobindo Pharma
We expect 37% YoY increase in net profit to Rs 6.17bn from Rs4.52bn, largely driven by strong revenue growth and 80bps YoY margin improvement.
We expect the ARV and controlled substance businesses to report good performance. We expect the growth momentum to continue in H2FY17 as the company has plans to launch 19 new products in the US market.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.